Revolade 25mg (Eltrombopag)

Introduction

Revolade 25mg is the name used to refer to Eltrombopag, which is an oral drug that is used to boost the number of platelets in people suffering from the condition of thrombocytopenia that is caused by various ailments. It’s a thrombopoietin-receptor agonist (TPO-RA) that increases platelet growth in the bone marrow. Revolade is recommended for conditions like immune thrombocytopenic purpura (ITP), as well as thrombocytopenia resulting from chronic Hepatitis C infection, and anemia that is aplastic.

What is Eltrombopag?

Eltrombopag is a synthesized non-peptide small-molecule thrombopoietin agonist. It is akin to the function of endogenous blood thrombopoietin (TPO), which is a natural hormone that regulates the production of platelets by megakaryocytes that reside in bone marrow.

Mechanism of Action

Eltrombopag connects to the transmembrane region of the thrombopoietin-related receptor (c-Mpl) on progenitors of megakaryocyte cells, and activates the JAK/STAT pathway of signaling. The activation stimulates the growth as well as differentiation of megakaryocytes that are precursor cells responsible for generating platelets.

Contrary to the endogenous thrombopoietin, this has an extracellular domain that it binds and binds to another receptor site that allows it to stimulate platelet production regardless of anti-TPO antibodies. This can be useful in thrombocytopenia caused by the immune system.

Indications and Uses

Revolade (Eltrombopag) is approved to treat:

1. Chronic Immune Thrombocytopenic Purpura (ITP):
   For adults with a weak reaction to corticosteroids, immunoglobulins, or surgery to remove the spleen. This helps to increase the number of platelets in order to decrease the risk of bleeding.
2. Thrombocytopenia in Chronic Hepatitis C Virus (HCV) Infection:
   Utilized to boost platelet counts to facilitate the beginning and continued maintenance of an interferon-based treatment, which could otherwise be restricted due to low levels of platelets.
3. Severe Aplastic Anemia:
   Utilized in conjunction with immunosuppressive therapy to treat those who have been resistant to treatment or have had an inadequate response to previous treatments.

Pharmacokinetics

• Absorption: Eltrombopag is absorbed easily orally. However, food items that contain calcium can decrease the absorption. It is suggested to consume it with a full stomach at least 2 hours prior to or following meals that contain calcium.
• Distribution: Highly bound to plasma proteins (>99%).
• Metabolism: It is primarily metabolized in the liver through CYP1A2 as well as UGT1A1 enzymes.
• Elimination: Most of the time, it is excreted through feces and has a half-life range of 21-32 hours. This allows once-a-day doses.

Dosage and Administration

• Initial dose:
  • For ITP: 50 mg twice daily in adults. 25 mg every day for patients with East Asian ancestry due to the increased exposure to drugs.
  • For thrombocytopenia associated with HCV therapy: 25 mg twice daily. The dose is adjustable depending on the platelet response.
  • For severe aplastic anemia: typically 50 mg once a day, which is titrated based on the platelet count.
• Dose adjustments:
  The doses can be adjusted based on the count of platelets, which is usually taken regularly. The aim is to ensure the amount of platelets needed to decrease bleeding risk, while avoiding bleeding thrombocytosis (platelets >400,000/µL).
• Administration:
  Consume orally when you have an empty stomach. Separate from food items containing calcium minimum of 2 hours before or 4 hours after.

Clinical Benefits

• Increased platelet counts: Lowers the chance of bleeding in those suffering from thrombocytopenia.
• Improved ability to undergo other therapies: Particularly for HCV sufferers, the eltrombopag permits the secure use of interferon-based antiviral therapies.
• Improved quality of life: Patients are less likely to experience bleeding episodes and associated complications.

Side Effects

Common side effects include:

• Headache
• Fatigue
• Nausea
• Upper respiratory tract infections
• Diarrhea
• Increased liver enzymes (transaminases)

More serious, but not as common adverse effects:

• Thromboembolic events: The risk of blood clots increases because of high platelet counts. It is imperative to monitor blood flow.
• Hepatotoxicity: Elevated liver enzymes or liver damage; regular liver function tests are necessary.
• Bone marrow fibrosis: Very rare cases are reported. Monitoring by blood count and examinations of bone marrow might be necessary.
• Cataracts: There are reports of either new or worsening cataracts.
• Hypersensitivity reactions: Rare allergic reactions.

Precautions and Contraindications

• Contraindications:
  Hypersensitivity to eltrombopag or other ingredients that make up the composition.
• Use with caution in:
  • Patients who have a history of a thromboembolic condition.
  • Liver function impairments in those with liver issues must be monitored closely.
  • People who are taking medications that affect platelet counts or the clotting process.
• Pregnancy and lactation:
  The safety of the product isn’t well-established. It is recommended to only use it when necessary.
• Drug interactions:
  Do not use multivalent Cations (calcium or magnesium supplements) in the same dose because of the lower absorption. Alter the timing of administration according to.

Monitoring

• Platelet counts: Weekly until stability is achieved, after which it becomes a monthly.
• Liver function tests: Before starting treatment, and frequently afterward.
• Signs of thromboembolism: Examine your symptoms for an abrupt swelling, pain, or shortness of breath.
• Ophthalmologic exams: The baseline and then every few months if needed.

Patient Counseling Points

• Drink Revolade on an empty stomach. Separate from calcium-rich foods 2 hours before or four hours following.
• Be sure to take blood tests regularly for monitoring platelet counts or liver function.
• Inform us of any unusual bleeding, swelling, indications of bleeding, or jaundice.
• Tell your doctor about the medications and supplements that you take.
• Do not engage in activities that could create a risk of bleeding or injury until the platelet count improves.

Conclusion

Revolade 25mg (Eltrombopag) is an important therapeutic drug in the treatment of thrombocytopenia resulting from ITP and chronic liver disease C treatment, as well as anemia aplastic. The ability of Revolade to increase the production of platelets is a significant benefit in reducing the risk of bleeding as well as providing other treatment options. Monitoring, careful dosing, and education of patients are vital for optimizing outcomes and minimizing dangers like thrombosis as well as liver toxicities.